Your Health, We Care
Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma 4 with BRAF V600E mutation as detected by an FDA-approved test.
Limitation of use: Dabrafenib is not indicated for treatment of patients with wild-type BRAF 6 melanoma .
from FDA,2013.05
Dabrafenib is a selective BRAF serine-threonine kinase inhibitor that exerts ant···【more】
Release date：2026-03-19Recommended：58
Dabrafenib is a kinase inhibitor developed by Novartis Pharmaceuticals. It was f···【more】
Release date：2026-03-19Recommended：43
Patients with unresectable or metastatic melanoma with BRAF V600E mutation.【more】
Release date：2026-01-06Recommended：44
Dabrafenib is an important therapeutic drug that plays a key role in the treatme···【more】
Release date：2025-01-10Recommended：266
Dabrafenib is a targeted therapy drug with a specific scope of application in cl···【more】
Release date：2025-01-10Recommended：300
